Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-06
1999-09-28
Lankford, Jr., Leon B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, 514171, 514412, 514561, 514899, A61K 3800, A61K 3140, A01N 4338
Patent
active
059588780
ABSTRACT:
The symptoms of the climacterium are ameliorated by the administration to an afflicted individual one or both of a nitric oxide substrate and/or nitric acid donor, alone or optionally in combination with a progestin or, in the case of a non-pregnant female, either a progestin or an estrogen or both.
REFERENCES:
patent: 5508045 (1996-04-01), Harrison et al.
Chaves et al. Braz. J. Med. Biol. Res. vol. 26, pp. 853-857, 1993.
Svarvas, F. Therrapia Hungarica. vol. 38(2), pp. 47-56, Abstract enclosed, 1990.
Reisert, P. Therapiewoche. vol. 37(6), pp. 1421-1424, Abstract enclosed, 1987.
Hendy et al. Maturitas. vol. 7/2, pp. 169-174, Abstract enclosed, 1985.
Danner et al. Intl. J. Androl. vol. 3(4), pp. 429-435, Abstract enclosed, 1980.
Krause, W. Fortschritte Der Medizin. vol. 108(19), pp. 371-374, Abstract enclosed, 1990.
Greenblatt et al. J. Am. Geriatr. vol. 27(11), pp. 481-490, Abstract enclosed, 1979.
*Bayhi et al., J. Clin. Anesth., 4:487-488 (1992).
*Conrad, FASEB, 7:566-571 (1993).
*Diamond, J. of Pharm. & Exp. Thera., 168(1):21-30 (1969).
*Garfield et al., "Control of Myometrial Contractility and Labor," Basic Mechanisms Controlling Term and Preterm Labor, Springer-Verlag Berlin, eds. Chwalisz et al. (1994).
Yallampalli et al., Soc. Gynecol. Invest. Abst. P41 (1993).
*Greenspoon et al., Lancet, 338:124 (1991).
*Izumi et al., Am. J. Obstet. Gynecol., 170:236-245 (1994).
*Jennings et al., J. of Mat. Fetal Med., 2:170-175 (1993).
*Lees et al., Lancet, 343:1325-1326 (1994).
*Natuzzi et al., Biochem. & Biophys. Res. Comm., 194(1):1-8 (1993).
*Papka et al., Neuroscience Letters, 147:224-228 (1992).
*Ramsey et al., Europ. J. of Clinical Investigation, 24:76-78 (1994).
*Sladek et al., Am. J. Obstet. Gynecol., 169:1285-1291 (1993).
*Yallampalli et al., Am. J. Obstet. Gynecol., 169:1316-1320 (1993).
*Yallampalli et al., Endocrinology, 133(4):1899-1904 (1993).
*Yallampalli et al., Am. J. Obstet. Gynecol., 170:175-185 (1993).
*Yallampalli et al., Endocrinology, 134(4):1971 (1994).
Bukowski Radoslaw
Chwalisz Krzysztof
Garfield Robert E.
Yallampalli Chandra
Board of Regents University of Texas
Lankford , Jr. Leon B.
Schering Aktiengesellschaft
Tate Christopher R.
LandOfFree
Treatment of climacteric disorders with nitric oxide synthase su does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of climacteric disorders with nitric oxide synthase su, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of climacteric disorders with nitric oxide synthase su will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-703200